


MOLECULAR DETECTION AND SCCMEC ELEMENT MOLECULAR TYPING OF COMMUNITY-ACQUIRED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS AT A TERTIARY CARE CENTRE AT NORTH INDIA.

Microbiology

Dr. Atul Khajuria* Assistant Professor, Microbiology, World College of Medical Sciences and Research Jhajjar, Haryana. *Corresponding Author



ABSTRACT

This prospective, cross-sectional study was conducted from October 2018 to April 2020, in the Department of Microbiology, at a tertiary care hospital. A total of 459 isolates were recovered from SSTIs, using strict aseptic precautions and processed as per standard microbiological techniques for the recovery of *S. aureus* based on staining characteristics, growth on Blood, MacConkey and Mannitol salt agar and in accordance with standard protocols. Disk diffusion method, Oxacillin screen Agar, HiCrome™ MRSA, MIC Determination by the E-test was carried out. DNA was extracted and PCR-based genotypic confirmation of *S. aureus* 16sRNA, *mecA* and PVL gene were carried out. The second multiplex PCR was done for sub typing the SCC *mec* elements. Out of 165 CA-MRSA isolates (n=157, 95%) had the presence of *mecA* gene and PVL gene was present in 68% (n=113). All the 165 CA-MRSA were typed by multiplex PCR out of which SCCmec type IVa was present in 26% (n=43), SCCmec type IVc was detected in 19% (n=32) and 38 (23%) isolates had the presence of SCCmec type V.

KEYWORDS

Staphylococcus aureus, CA-MRSA community-acquired MRSA, SSTI -skin and soft tissue infection, SCC- staphylococcal cassette chromosome, PVL- Pantan-valentine leukocidin

INTRODUCTION

Staphylococcus aureus is a highly successful opportunistic pathogen. It is a ubiquitous colonizers of the skin and mucosa of humans and animals; *S. aureus* has an extraordinary capacity to adapt and survive in a great variety of environments. Staphylococci are nonmotile, non-spore forming, and usually catalase positive, and they are often unencapsulated. In humans, *S. aureus* has a niche preference for the anterior nares, especially in adults, and is shed onto healthy skin, including axilla and perineum. *S. aureus* can exist as a resident or a transient member of the normal flora. Nasal carrier rate varies from 10% to 40% in CA-MRSA and can produce a wide variety of diseases, the resistance gene sought is *mecA*, which encodes low-affinity penicillin-binding protein A (PBP2A).^{[1][2][3]}

Panton-valentine leukocidin. PVL is a peculiar homologue of Hlg, which was originally reported in 1932 by Panton and Valentine encoded by two genes, *lukS* and *lukF*, which can assemble either between themselves or with the components of Hlg, thus producing chimera complexes. PVL is encoded by mobile phages, the prevalence rate of PVL is usually low ($\leq 2\%$) in MSSA and is present in almost 100% of isolates of CA-MRSA associated with skin and soft tissue infection (SSTI) and severe hemorrhagic pneumonia in children and young adults.^{[1][2][3]}

Resistance Island Staphylococcal Cassette Chromosome *mec*

MRSA contains one resistance island called *staphylococcal cassette chromosome (SCC) mec*, wherein *mec* is the genetic element that confers resistance to methicillin. SCCmec is an exogenous piece of DNA that may vary between 15 and 60 kb. The SCCmec critical genes are the recombinases *ccrA/ccrB* and *ccrC*, which can mediate mobilization of the whole element, and the *mecA* gene, which mediate and confers intrinsic resistance of MRSA to almost all β -lactams. Several types of SCCmec have evolved from more generalist SCC cassettes, which are structures able to integrate a variety of genes and are functional equivalents to integrons in gram-negative bacteria.^{[1][2][3]}

SCCmec types I, II, and III were belong to HCA-MRSA. They harbor multiple resistance determinants, they have relatively large sizes (35–60 kb), and they are therefore difficult to mobilize. Types IV, V, and VI were associated with CA-MRSA. They are much smaller (about 15 kb) than their hospital congeners and carry multiple antibiotic-resistance genes. However, associated with other elements like PVL and multiple SE genes. SCCmec typing is important to understand the epidemiology and clonal relatedness of MRSA strains. Keeping this background, the present study was conducted to detect and molecular subtypes SCCmec in CA-MRSA strains isolated from our institution.

MATERIAL AND METHODS

Study design and setup

This prospective, cross-sectional study was conducted from October 2018 to April 2020, in the Department of Microbiology, and affiliated tertiary care hospital. A total of 459 isolates were recovered from SSTIs from different outpatients (one isolate per patient). Samples

were collected from patients, using strict aseptic precautions and in were processed as per standard microbiological techniques for the recovery of *S. aureus* based on staining characteristics, growth on Blood, MacConkey and Mannitol salt agar and spot tests like catalase, slide and tube coagulase, bacitracin resistance, Furazolidone sensitivity, Deoxyribonuclease (DNase) Test, Phosphatase Test, Mannitol Fermentation Test and the modified Hugh and Leifson's (OF) test in accordance with standard protocols^[4] and immediately processed without any delay. Inclusion criterion for the study was followed as per definition of CA-MRSA by CDC-2000.

Antimicrobial susceptibility testing

The antimicrobial susceptibility test was performed by the Kirby Bauer's disc diffusion technique on Cation adjusted Mueller–Hinton agar, as per Clinical Laboratory Standard Institute (CLSI) guidelines.^[5,6] The antibiotics tested were as follows (potency in $\mu\text{g}/\text{disc}$): penicillin (10 units), ciprofloxacin (5 μg), clindamycin (2 μg), erythromycin (15 μg), cotrimoxazole (1.25/23.75 μg), linezolid (30 μg) vancomycin (30 μg) and netilmicin (30 μg). Methicillin resistance was detected using cefoxitin (30 μg) discs (Table 1). All the discs were procured from Hi-Media Mumbai. The susceptibility patterns were graded as sensitive, intermediate and resistant as per CLSI guidelines.^[5,6]

MIC Determination

Minimum inhibitory concentrations (MIC) of antibiotics were determined by the E-test (bioMérieux, Marcy l'Etoile, France) However, vancomycin resistance was detected by Vancomycin Screen Agar and E Test both.

Detection of MRSA by phenotypic methods

Disk diffusion methods.

Disk diffusion method technique on Cation adjusted Mueller–Hinton agar, as per Clinical Laboratory Standard Institute (CLSI) guidelines were performed for all isolates using oxacillin and cefoxitin disks. The turbidity of suspension was adjusted as per McFarland standard turbidity and both oxacillin and Cefoxitin disk were placed aseptically on the Mueller–Hinton agar and incubated at 35°C for 18 h. The inhibition zone for each antibiotic disks were measured and by referring to CLSI guidelines reported as MRSA or methicillin susceptible *S. aureus*.^[5,6] All of antibiotic disks were provided from (Hi-Media Mumbai)

Oxacillin screen Agar

Muller-Hinton agar plates containing 4% NaCl and 6 $\mu\text{g}/\text{ml}$ of oxacillin were prepared. To perform the oxacillin screen test, a swab dipped in 0.5 McFarland's suspension of the isolate was deposited as a spot on the agar surface and it was incubated at 35 °C for 24 h. Plates were observed carefully in transmitted light for any growth. Any growth after 24 h was considered oxacillin resistant.^[5,6]

HiCrome™ MRSA

HiCrome™ Rapid detection media for detection of MRSA was procured from Hi-Media laboratory Mumbai. Peptone provide the

essential nutrients along with carbonaceous, nitrogenous and Vitamin B complex nutrients. The chromogenic mixture in the medium specifically cleaved by *Staphylococcus aureus* to give green coloured colonies. With the addition of both MeReSa Supplement (FD229) and Cefoxitin supplement (FD259) in medium it was made selective for MRSA.

Quality control

The quality control strains including methicillin resistant *S. aureus* (MRSA ATCC 43300), methicillin sensitive *S. aureus* (MSSA ATCC 25293), ATCC MRSA 33592, BAA-41, 42, 44, 1683 and MRSA BAA-2094 were used as positive and negative controls. These strains were procured from Hi-Media laboratory Mumbai.

DNA extraction and Molecular detection

DNA was extracted from the Confirmed strains of MRSA using the spin column method (QIAGEN; GmbH, Hilden, Germany) as per manufacturer's instructions. PCR-based genotypic confirmation of *S. aureus* 16S rRNA, *mecA* and *PVL* gene were carried out on the isolates by using Gene Amp 9700 PCR System (Applied Biosystems, Singapore) (Table 2). The second multiplex PCR was done for typing and sub typing the SCCmec elements of MRSA. Eight pairs of primers were used including the unique and specific primers for SCCmec types (subtypes) I, II, III, IVa, IVb, IVc, IVd and V (Table 3).

MRSA ATCC 43300, MSSA ATCC 25293, ATCC MRSA 33592 for SCCmec: Type III, ATCC MRSA BAA-41 for SCCmec: Type II, ATCC MRSA BAA-42 for SCCmec: Type VI, ATCC MRSA BAA-44 for SCCmec: Type I, ATCC MRSA BAA-1683 for SCCmec: Type IV a and *pvl* positive, ATCC MRSA BAA-2094 for SCCmec: Type V and *pvl* negative, *mecA* positive were used as positive and negative controls for Quality control. PCR products were run on 1.5% agarose gel, stained with ethidium bromide visualized under UV light and photographed. Reactions were incubated at 95°C for 10 minutes followed by 35 cycles of 95°C for 15 seconds, 55°C for 30 seconds, and 72°C for 30 seconds. The final extension was at 72°C for 10 minutes. The amplicons were purified using QIAquick PCR purification kit (QIAGEN; GmbH, Hilden, Germany). The PCR products were visualized on a 1.5% agarose gel with ethidium bromide dye under a UV transilluminator. Sequences were compared with known sequences using the BLAST facility (<http://blast.ncbi.nlm.nih.gov>).

Statistical analysis

Statistical analysis was done using SPSS 16 software. The prevalence of resistance to each antimicrobial agent were recorded as percentage.

RESULT AND DISCUSSION –

A total of 459 *Staphylococcus aureus* isolates were recovered from SSTIs from different outpatients. (one isolate per patient). Out of A total of 459 recovered from OPD samples (CA-MRSA) 35.9% (n=165) were found to be methicillin resistant. Out of 165 CA-MRSA isolates (n=157, 95%) had the presence of *mecA* gene and *PVL* gene was present in 68% (n=113). All the 165 CA-MRSA were typed by multiplex PCR out of which SCCmec type IVa was present in 26% (n=43), SCCmec type IVc was detected in 19% (n=32) and 38 (23%) isolates had the presence of SCCmec type V. None of the CA-MRSA isolates harboured SCCmec types I, II, and III. 100% of CA-MRSA isolates harboured SCCmec types I, II, and III. 100% of CA-MRSA isolates resistant against Penicillin, Methicillin and Oxacillin. All these isolates showed 35% (n=58) resistant to Gentamicin, 38% (n=63) resistant to clindamycin, 42% (n=70) resistant to ciprofloxacin, 48% (n=79) resistant to Cotrimoxazole and 64% (n=106) resistant to erythromycin (Table 1). However, there was no isolate which was resistant to linezolid, Daptomycin, Teicoplanin and vancomycin (Table 1). All these resistant CA-MRSA resistant isolates had shown MIC ≤ 0.5 against vancomycin while MIC > 4 (R) against clindamycin, erythromycin and oxacillin. This study highlights both phenotypic and genotypic methods for the identification of CA-MRSA. The novel features were reporting of multidrug resistant CA-MRSA in communities. This study for the first time reported SCCmec type V, SCCmec type IVc and SCCmec IVa the prevalent circulating strain among CA-MRSA. There is an ongoing change in prevalence, resistance profile and epidemiology of CA-MRSA strains.

CONCLUSION -

The highlights of this study included compiled, simple and easy format for the identification, susceptibility testing by using both phenotypic and genotypic methods for CA-MRSA. The novel features were

reporting of multidrug resistant CA-MRSA in communities. For the first time from the local community, this study had reported the prevalent circulating strain of Novel SCCmec type V, SCCmec type IVc and SCCmec IVa subtype.

Funding: No external funding or grant for this research.

Conflict of Interest: The author state None to declare.

Table 1: Showing Antibigram and resistance percentage of CA-MRSA strains

Antibiotics	Number Resistance	Percentage
Penicillin(10units)	165	100%
Erythromycin(15µg)	106	64%
Azithromycin(15µg)	106	64%
Co-trimoxazole (1.25/23.75µg)	79	48%
Clindamycin(2µg)	63	38%
Ciprofloxacin (5µg)	70	42%
Gentamicin (10µg)	58	35%
Netilmicin(30µg)	59	35%
Linezolid (30µg)	0	0%
Teicoplanin (30µg)	0	0%
Vancomycin(30µg)	0	0%

Table 2: Primer sequences used for the confirmation of *S. aureus* and detection of *mecA* and *PVL* gene.

Primer name	Target gene	Sequence	Amplicon size
<i>mecA</i> (F)	<i>mecA</i>	AAAATCGATGGTAAAGGTTGGC	533 bp
<i>mecA</i> (R)		AGTTCTGCAGTACCGGATTTC	
<i>mecA</i> F	<i>mecA</i>	TCCAGATTACAACCTTCACCAGG	162 bp
<i>mecA</i> R		CCACTTCATATCTTGTAACG	
Staph (F)	16s	AACTCTGTTATTAGGGAAGAAC	756 bp
Staph (R)	Rna	CCACCTTCCTCCGGTTTGTCAAC	
Luk-PV-1	LukS/F-PV	ATCATTAGGTAAAATGTCTGGA	433 bp
Luk-PV-2		CATGATCCA	
		GCATCAAGTGTATTGGATAGCA	
		AAAGC	

Table 3: Primer sequences used for typing and sub typing MRSA strains.

Primer name	Target gene	Primer sequence	Amplicon size
SCCmec I F	SCCmec I	GCTTTAAAGAGTGTCGT	613bp
SCCmec I R		TACAGG	
SCCmec II F	SCCmec II	GTTCTCTCATAGTATGAC	398bp
SCCmec II R		GTCC	
SCCmec III F	SCCmec III	CGTTGAAGATGATGAAG	280bp
SCCmec III R		CGAAATCAATGGTTAAT	
SCCmec IVa F	SCCmec IVa	GGACC	776bp
SCCmec IVa R		GCCTTATTCGAAGAAAC	
SCCmec IVb F	SCCmec IVb	CG	493bp
SCCmec IVb R		CTACTCTCTGAAAAGC	
SCCmec IVc F	SCCmec IVc	GTCC	200bp
SCCmec IVc R		TCTGGAATTACTTCAGC	
SCCmec IVd F	SCCmec IVd	TGC	881bp
SCCmec IVd R		AAACAATATTGCTCTCC	
SCCmec V F	SCCmec V	CTCAAAATACGGACCCC	325bp
SCCmec V R		AATACA	
		TGCTCCAGTAATTGCTA	
		AAG	
		GAACATTGTTACTTAAA	
		TGAGCG	
		TGAAAGTTGTACCCTTG	
		ACACC	

REFERENCES-

1. Que, Y.A., Moreillon, P. 2010. *Staphylococcus aureus* (Including Staphylococcal Toxic Shock). In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's Principle and practice of Infectious Diseases. 7th ed. Philadelphia: Churchill Livingstone; p.2543-78.
2. Zhang K, McClure JA, Elsayed S, Louie T, Conly JM. 2005. Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec Types I to V in methicillin resistant *Staphylococcus aureus*. J Clin Microbiology. 43(10):5026-33.
3. Moussa I, Kabli SA, Hemeg HA, Al-Garni SM, Shibl AM. 2012. A novel multiplex PCR for molecular characterization of MRSA recovered from Jeddah, kingdom of Saudi Arabia. Indian J Med Microbiol. 30(3):296-301.
4. Collee JG, Miles RS, Wan B. 1996. Tests for the identification of bacteria. In: Collee JG, Fraser AG, Marmion BP, Simmons A editor. Mackie and Mc Cartney Practical Medical Microbiology. 14th ed.. Edinburgh: Churchill Livingstone; P 131–150.
5. CLSI. 2017. Performance Standards for Antimicrobial Susceptibility Testing. M100-S27. Clinical and Laboratory Standards Institute, Wayne, PA.
6. CLSI. 2019. Performance Standards for Antimicrobial Susceptibility Testing. M100-S29. Clinical and Laboratory Standards Institute, Wayne, PA.